{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:17Z","timestamp":1772119997248,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12032-021-01620-9","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T06:04:44Z","timestamp":1641276284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors"],"prefix":"10.1007","volume":"39","author":[{"given":"Chang-Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Ting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Xing","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Qin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Tao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8127-3884","authenticated-orcid":false,"given":"Xiao-Long","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"1620_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ijc.11099","volume":"105","author":"EA Engels","year":"2003","unstructured":"Engels EA, Pfeiffer RM. Malignant thymoma in the United States:demographic patterns in incidence and associations withsubsequent malignancies. Int J Cancer. 2003;105:546\u201351.","journal-title":"Int J Cancer"},{"key":"1620_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","volume":"9","author":"A Marx","year":"2014","unstructured":"Marx A, Str\u00f6bel P, Badve SS, Chalabreysse L, Chan JK, Chen G, et al. ITMIG consensus statement on theuse of the WHO histological classification of thymoma and thymiccarcinoma: Refined definitions, histological criteria, and reporting. JThorac Oncol. 2014;9:596\u2013611.","journal-title":"JThorac Oncol"},{"issue":"7","key":"1620_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","volume":"6","author":"N Girard","year":"2011","unstructured":"Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011;6(7):1749\u201355.","journal-title":"J Thorac Oncol"},{"issue":"15","key":"1620_CR4","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. A phase II study of carboplatinplus paclitaxel in advanced thymoma or thymic carcinoma. J Clin Oncol. 2011;29(15):2060\u20135.","journal-title":"J Clin Oncol"},{"key":"1620_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","volume":"67","author":"S Igawa","year":"2010","unstructured":"Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer. 2010;67:194\u20137.","journal-title":"Lung Cancer"},{"key":"1620_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000097944","volume":"70","author":"R Maruyama","year":"2006","unstructured":"Maruyama R, Suemitsu R, Okamoto T, Kojo M, Aoki Y, Wataya H, et al. Persistentand aggressive treatment for thymic carcinoma. Results of a single-instituteexperience with 25 patients. Oncology. 2006;70:325\u20139.","journal-title":"Oncology"},{"key":"1620_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastaticcolorectal cancer. N Engl J Med. 2004;350:2335.","journal-title":"N Engl J Med"},{"issue":"19","key":"1620_CR8","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","volume":"33","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, Phase III study of first-line\u00a0carboplatin\/paclitaxel plus bevacizumab or placebo\u00a0in chinese\u00a0patients\u00a0with advanced or recurrent nonsquamous\u00a0non-small-cell\u00a0lung\u00a0cancer. J Clin Oncol. 2015;33(19):2197\u2013204.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1620_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. N Engl J Med. 2014;370(8):734\u201343.","journal-title":"N Engl J Med"},{"key":"1620_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/JTO.0000000000000296","volume":"9","author":"MF Benveniste","year":"2014","unstructured":"Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol. 2014;9:119\u201324.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"1620_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer AVAil. J Clin Oncol. 2009;27(8):1227\u201334.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1620_CR12","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1016\/j.cllc.2018.06.005","volume":"19","author":"M Imbimbo","year":"2018","unstructured":"Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, et al. RELEVENT Trial: Phase II trial of ramucirumab, carboplatin, and paclitaxel in previously untreated thymic carcinoma\/B3 thymoma with area of carcinoma. Clin Lung Cancer. 2018;19(5):e811\u20134.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"1620_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1556-0864(15)31586-0","volume":"1","author":"M Lucchi","year":"2006","unstructured":"Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, et al. Neoadjuvant chemotherapy for stage III and IVA thymomas a single-institution experience with a long follow-up. J Thorac Oncol. 2006;1(4):308\u201313.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1620_CR14","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","volume":"9","author":"A Inoue","year":"2014","unstructured":"Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, et al. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma North Japan Lung Cancer group study 0803. J Thorac Oncol. 2014;9(12):1805\u20139.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1620_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/annonc\/mdu541","volume":"26","author":"F Hirai","year":"2015","unstructured":"Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26(2):363\u20138.","journal-title":"Ann Oncol"},{"issue":"5","key":"1620_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"1620_CR17","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144\u201350.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1620_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Di\u00e9ras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1 randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252\u201360.","journal-title":"J Clin Oncol"},{"key":"1620_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreatedlocally advanced or metastatic non\u2013small-cell lungcancer. J Clin Oncol. 2004;22:2184\u201391.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1620_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/JTO.0b013e318265b500","volume":"7","author":"A Lopez-Chavez","year":"2012","unstructured":"Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol. 2012;7(11):1707\u201312.","journal-title":"J Thorac Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01620-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T04:17:32Z","timestamp":1643343452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01620-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01620-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-853843\/v1","asserted-by":"object"}]},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"26 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by our institutional ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave their consent for receiving this new chemotherapy regimen and for the use of their information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"25"}}